Loading...
NPI 1861137481 · Pompano Beach, FL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Biogroup Laboratory Corp is a clinical medical laboratory provider located in Pompano Beach, Florida. This profile covers 36 Medicare and 26 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Biogroup Laboratory Corp |
| Address | 2769 E Atlantic Blvd |
| City | Pompano Beach |
| State | FL |
| ZIP | 33062 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | April 28, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $24.8M |
| Medicaid | $21.3K |
BIOGROUP LABORATORY CORP is operating as a high-throughput molecular/genetic testing laboratory: its top-billed Medicare procedures are largely full-gene and targeted sequence analyses (BRCA2/PALB2 81307, PTEN 81321, TP53 81351 and many others), with procedure-level volumes in the thousands (for example, 81321 has 4.1K claims, $588 avg paid/claim) consistent with a centralized genetics lab processing many specimens. The CPT mix—BRCA, TP53, KRAS, BRAF and multiple hereditary cancer panel codes—points to a service line focused on oncology and hereditary risk molecular diagnostics rather than routine clinical chemistry.
Medicare revenue is concentrated but not concentrated to a single code: the provider's top three Medicare codes (81307, 81321, 81351) account for 29.9% of its total Medicare revenue, with those codes generating $2.6M (10.7%), $2.4M (9.9%), and $2.3M (9.4%) respectively. This concentration indicates a meaningful reliance on a small set of high-revenue genetic assays within a larger portfolio of molecular tests.
Despite being recently enumerated on 2022-04-28 (~4 years ago), BIOGROUP shows national-scale activity for many molecular assays: multiple Medicare codes rank at or near the top nationally—81351 ranks #1 of 24 providers (100th percentile; extreme outlier), 81307 ranks #2 of 62 (98th percentile; extreme outlier), and 81321 ranks #2 of 37 (97th percentile; extreme outlier). These high national ranks and characterizations as "extreme outlier" or "notably above typical" suggest the lab is a major national processor for specific genomic tests rather than a small local lab.
The provider's Medicaid footprint is minimal in absolute dollars: total Medicaid revenue is $21.3K compared with $24.8M from Medicare, making Medicaid effectively a negligible contributor to overall revenue. Although the top three Medicaid codes (81162, 81292, 81210) account for 64.3% of Medicaid revenue, those dollars are small in absolute terms (81162 generates $8.4K, 39.7% of Medicaid revenue), so Medicaid does not materially change the provider's payer risk profile.
On Medicaid the provider is not a dominant in-state competitor: 81162 ranks #5 of 8 providers in-state (43th percentile; typical) and other top Medicaid codes occupy low to mid state percentiles, indicating modest market share in Florida Medicaid for these genetic assays. The contrast between national leadership on Medicare for many assays and modest in-state Medicaid rankings implies the lab's scale and referral network are weighted toward Medicare-population testing and possibly national commercial/physician referrals rather than state Medicaid panels.
A large portion of Medicare revenue is driven by many codes flagged as statistical outliers or notably above typical national volume: examples include 81334 (ranks #1 of 22, 100th percentile; extreme outlier), 81223 (ranks #2 of 68, 99th percentile; extreme outlier), and 81311 (ranks #1 of 29, 100th percentile; extreme outlier). This pattern—numerous high-volume, high-rank molecular codes—supports an operational profile of specialized, volume-driven genetic testing capacity that consistently outpaces typical national providers for these assays.
The provider’s CPT mix and revenue profile imply business implications for payers: given $24.8M in Medicare revenue with heavy weighting toward complex molecular assays, payers engaging BIOGROUP should expect a vendor that primarily supplies advanced genetic diagnostics (hereditary cancer panels, oncogenic hotspot testing, and targeted gene sequencing) rather than routine laboratory services. Contracting, network inclusion, and utilization oversight should therefore focus on molecular test appropriateness, panel definitions, and referral pathways rather than standard laboratory service lines.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
36 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 3,920 | $660 | $2.6M |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 4,100 | $590 | $2.4M |
| 81351 | The lab analyst performs the technical lab test on a specimen such as blood to analyze the entire gene sequence for the tumor protein 53 (TP53) gene, which may indicate a diagnosis of Li–Fraumeni… | 3,630 | $630 | $2.3M |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 3,350 | $590 | $2M |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 3,220 | $590 | $1.9M |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 3,330 | $490 | $1.6M |
| 81334 | The lab analyst performs the technical lab test to detect the presence of specific changes in the runt related transcription factor 1 (RUNX) gene for targeted sequence analysis, such as exons 3–8. | 4,390 | $320 | $1.4M |
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 780 | $1,790 | $1.4M |
| 81311 | The lab analyst performs the technical lab test to analyze variants in exon 2, such as codons 12 and 13, and exon 3, such as codon 61, for the neuroblastoma RAS viral, v–ras, oncogene homolog, also… | 3,460 | $290 | $1M |
| 81320 | The lab analyst performs the technical lab test to detect the presence of common changes in the phospholipase C gamma 2 gene (PLCG2). | 3,460 | $290 | $988.1K |
Showing 1–10 of 36
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 36 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
36 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81307 | 1 | 30 | 320 | $660 | $508.3K |
| 81321 | 1 | 30 | 430 | $580 | $467.7K |
| 81238 | 1 | 20 | 330 | $590 | $440.3K |
| 81162 | 2 | 20 | 100 | $1,780 | $403.3K |
| 81249 | 1 | 20 | 290 | $590 | $383.1K |
| 81223 | 1 | 20 | 340 | $490 | $329.3K |
| 81351 | 1 | 20 | 210 | $630 | $307.8K |
| 81334 | 1 | 20 | 390 | $320 | $295.7K |
| 81314 | 2 | 10 | 980 | $320 | $263.3K |
| 81311 | 1 | 20 | 270 | $290 | $213K |
Showing 1–10 of 36
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
26 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 70 | $120 | $8.4K |
| 81292 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutL homolog 1, or MLH1 gene, also known as the colon cancer or nonpolyposis type 2 gene. | 50 | $50 | $2.7K |
| 81210 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for B–Raf proto–oncogene, serine/threonine kinase, also known as BRAF. | 50 | $50 | $2.5K |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 50 | $40 | $2.2K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 50 | $20 | $1.3K |
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 70 | $10 | $910 |
| 81295 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 2, or MSH2 gene, also known as the colon cancer or nonpolyposis type 1 gene. | 50 | $10 | $760 |
| 81345 | The lab analyst performs the technical lab test to analyze targeted genes, such as the promotor region for the telomerase reverse transcriptase gene (TERT). | 80 | $10 | $490 |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 80 | $1 | $330 |
| 81351 | The lab analyst performs the technical lab test on a specimen such as blood to analyze the entire gene sequence for the tumor protein 53 (TP53) gene, which may indicate a diagnosis of Li–Fraumeni… | 80 | $1 | $330 |
Showing 1–10 of 26
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
26 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 8 | 10 | 80 | $50 | $2.4M |
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 5 | 10 | 120 | $370 | $67K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 8 | 10 | 90 | $90 | $15K |
| 81292 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutL homolog 1, or MLH1 gene, also known as the colon cancer or nonpolyposis type 2 gene. | 8 | 10 | 170 | $70 | $11.1K |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 8 | 10 | 70 | $60 | $10.3K |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 8 | 20 | 80 | $40 | $10.1K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 8 | 10 | 80 | $50 | $9.4K |
| 81210 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for B–Raf proto–oncogene, serine/threonine kinase, also known as BRAF. | 3 | 10 | 90 | $20 | $6.4K |
| 81241 | The lab analyst performs the technical lab test to detect the presence of a common change, called the Leiden variant, in the gene for coagulation factor V, also known as Factor V Leiden or F5. | 10 | 20 | 80 | $10 | $6.1K |
| 81295 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 2, or MSH2 gene, also known as the colon cancer or nonpolyposis type 1 gene. | 8 | 10 | 170 | $40 | $6.1K |
Showing 1–10 of 26
Other providers in the same ZIP code as Biogroup Laboratory Corp, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| John Coats | FL | Neurological Surgery Physician | $90.6K | $0 |
| Dahlia Khanns | FL | Family Nurse Practitioner | $73.6K | $440 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.